Lycia Therapeutics awards Touami 68,755 stock options

The award predated Lycia’s registration of an equity class under Section 12 in connection with its initial public offering.

Rhea-AI Filing Summary

Lycia Therapeutics, Inc. Chief Business Officer Sofia Touami received a direct award of stock options covering 68,755 shares of common stock on August 11, 2026. The options have an exercise price of $3.70 per share and expire August 10, 2036. They vest at 1/48 of the award monthly over four years, with the first tranche vesting on September 6, 2026, subject to her providing service on each vesting date.

Insider Trade Summary

Grant/Award: 68,755 shares

Grant/Award 1 txn

Insider Touami Sofia

Role Chief Business Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2	68,755	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 68,755 contracts (Direct)

Footnotes (2)

1. F1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).
2. F2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Key Figures

Stock options awarded: 68,755 options Exercise price: $3.70 per share Vesting schedule: 1/48 of the award monthly over four years +1 more

4 metrics

Stock options awarded 68,755 options Award to Sofia Touami on August 11, 2026, covering 68,755 shares of common stock

Exercise price $3.70 per share Price to exercise the awarded options

Vesting schedule 1/48 of the award monthly over four years First tranche vesting on September 6, 2026, subject to service on each vesting date

Expiration date August 10, 2036 Awarded stock options

Key Terms

Stock Option (Right to Buy), vest, Rule 16a-2(a), Section 12 of the Exchange Act

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest financial

"options vest as to 1/48 of the total award monthly"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Rule 16a-2(a) regulatory

"reported herein pursuant to Rule 16a-2(a)"

Section 12 of the Exchange Act regulatory

"registration of a class of equity securities under Section 12 of the Exchange Act"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did LYCA Chief Business Officer Sofia Touami receive?

Sofia Touami received stock options covering 68,755 shares of common stock, with a $3.70-per-share exercise price and an expiration date of August 10, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/26/2026 - 08:21 PM EDT Accepted by SEC EDGAR 10/26/2026 - 07:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Touami Sofia

(Last) (First) (Middle)

C/O LYCIA THERAPEUTICS, INC.

400 EAST JAMIE COURT, SUITE 200

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lycia Therapeutics, Inc. [ LYCA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.7	08/11/2026(1)		A		68,755		(2)	08/10/2036	Common Stock	68,755	$0	68,755	D

Explanation of Responses:

1. The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a).

2. The options vest as to 1/48 of the total award monthly over four years, with the first tranche vested on September 6, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

	/s/ Amy Bachrodt, Attorney-in-Fact	10/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)